Whether you are a biotechnology, pharmaceutical, or medical device company, the future of your business will be shaped by your ability to navigate legal, regulatory, and economic hurdles of this dynamic industry. At Jenner & Block, we know the risks and opportunities our clients face in the lifecycle of their products. Our in-depth knowledge of the life sciences industry coupled with decades of experience handling ”bet-the-company” matters for our clients drive creative solutions in this fast-moving field.
Many team members have life sciences backgrounds—as former chemists, molecular biologists, chemical and biomedical engineers—allowing us to quickly comprehend complex topics and explain issues in terms our clients, judges, and juries understand. While many seek our deep intellectual property and patent experience, they also value the perspectives our litigation, capital markets, and M&A lawyers bring to reframing issues for better client outcomes.
Experience
- Represented a developer of biosimilar therapeutics on several matters regarding a PEGylated G-CSF drug product, patent portfolio analysis, and preparation of abbreviated biologic license applications. This work included district court litigation under the Biologics Price Competition and Innovation Act (BPCIA), appeal, and numerous inter partes reviews at the PTAB.
- Defended a multinational pharmaceutical and medical device company in a lawsuit concerning allegations of patent infringement related to fibrin tissue sealants and bandages.
- Conducted an in-depth inventorship analysis for a biotechnology company that covered its core technology for which a third party was also claiming inventorship rights.
- Represented Lonza Group in a $5.5 billion acquisition of Capsugel SA; $3.1 billion offering of ordinary shares to finance the purchase of Capsugel; $1.2 billion acquisition of Arch Chemicals; and acquisition of controlling interest in Octane Biotech.
- Represented NPS Pharmaceuticals in a $100 million follow-on public offering of common stock.
- Represented Clementia Pharmaceuticals in a $60 million cross-over round; $137 million initial public offering of common stock; $70 million follow-on public offering of common stock.
- Representation of a medical device manufacturer in qui tam litigation alleging false claims in connection with the sale of medical devices to VA medical centers.
- Represented a developer of biosimilar therapeutics in a multi-year trade secret litigation concerning a recombinant-DNA manufacturing process used to make an oncology drug product.
- Provided legal guidance to start-up battery manufacturing company with submittal of PMN notification under TSCA.
- Represented a defendant in a long-running antitrust class action lawsuit concerning the distribution of certain medical devices.
Chair
Chair